Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases

Author:

Dara Praneet12,Farooqui Zeba2,Mwale Fackson3,Choe Chungyoul4,van Wijnen Andre J.25ORCID,Im Hee-Jeong26ORCID

Affiliation:

1. Osteopathic Medical School, Des Moines University (DMU), Des Moines, IA 50312, USA

2. Department of Biomedical Engineering, University of Illinois at Chicago (UIC), Chicago, IL 60607, USA

3. Lady Davis Institute for Medical Research, SMBD-Jewish General Hospital, 3755 Cote Ste-Catherine Road, Room F-602, Montreal, QC H3T 1E2, Canada

4. Medical Research Institute, School of Medicine, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea

5. Department of Biochemistry, University of Vermont (UVM), Burlington, VT 05405, USA

6. Jesse Brown Veterans Affairs Medical Center at Chicago (JBVAMC), Chicago, IL 60612, USA

Abstract

Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatments for either rheumatoid arthritis (RA) or osteoarthritis (OA) is to reduce pain. Non-steroidal anti-inflammatory drugs, opioids, and opioid antagonists have each been considered in the management of chronic pain in arthritis patients. Naltrexone is an oral-activated opioid antagonist with biphasic dose-dependent pharmacodynamic effects. The molecule acts as a competitive inhibitor of opioid receptors at high doses. However, naltrexone at low doses has been shown to have hormetic effects and provides relief for chronic pain conditions such as fibromyalgia, multiple sclerosis (MS), and inflammatory bowel disorders. Current knowledge of naltrexone suggests that low-dose treatments may be effective in the treatment of pain perception in chronic inflammatory conditions observed in patients with either RA or OA. In this review, we evaluated the therapeutic benefits of low-dose naltrexone (LDN) on arthritis-related pain conditions.

Funder

NIH

DOD

VA Research Career Scientist Award

Veterans Affairs Merit Award

Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science and ICT

Technology Development Program

Ministry of SMEs and Startups

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Reference58 articles.

1. Institute of Medicine (2012). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, The National Academies Press.

2. Prevalence of chronic pain among adults in the United States;Yong;Pain,2022

3. Chronic pain: An update on burden, best practices, and new advances;Cohen;Lancet,2021

4. Trends in emergency physician opioid prescribing practices during the United States opioid crisis;Gleber;Am. J. Emerg. Med.,2020

5. Changes in opioid therapy use by an interprofessional primary care team: A descriptive study of opioid prescription data;Rosa;J. Manip. Physiol. Ther.,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3